Last reviewed · How we verify
Intravenous amiodarone(2)
Intravenous amiodarone(2) is a Class III antiarrhythmic agent Small molecule drug developed by Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud. It is currently FDA-approved for Atrial fibrillation with rapid ventricular response, Ventricular tachycardia, Ventricular fibrillation. Also known as: 72 hour amiodarone.
Intravenous amiodarone is a Class III antiarrhythmic agent that blocks potassium channels and prolongs the action potential duration and refractory period to restore normal heart rhythm.
Intravenous amiodarone is a Class III antiarrhythmic agent that blocks potassium channels and prolongs the action potential duration and refractory period to restore normal heart rhythm. Used for Atrial fibrillation with rapid ventricular response, Ventricular tachycardia, Ventricular fibrillation.
At a glance
| Generic name | Intravenous amiodarone(2) |
|---|---|
| Also known as | 72 hour amiodarone |
| Sponsor | Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud |
| Drug class | Class III antiarrhythmic agent |
| Target | Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amiodarone works primarily through potassium channel blockade, which delays repolarization and extends the action potential duration. It also has properties of all four Vaughan-Williams antiarrhythmic classes, including sodium channel blockade, beta-adrenergic antagonism, and calcium channel inhibition. This multi-channel activity makes it effective for suppressing various cardiac arrhythmias.
Approved indications
- Atrial fibrillation with rapid ventricular response
- Ventricular tachycardia
- Ventricular fibrillation
- Supraventricular tachycardia
Common side effects
- Hypotension
- Bradycardia
- Phlebitis at injection site
- Nausea
- Pulmonary toxicity (chronic use)
- Thyroid dysfunction (chronic use)
- Hepatotoxicity
Key clinical trials
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Heart Rhythm Changes in Patients With Atrial Fibrillation After Cardiopulmonary Bypass: a Retrospective Analysis
- Circumferential Pulmonary Vein Isolation Plus Transition Zone Modification in Atrial Fibrillation Patients Without Low-Voltage Areas (NA)
- Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter (PHASE4)
- Pulmonary Vein Isolation in Typical Atrial Flutter and Heart Failure (NA)
- Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation (PHASE4)
- Efficacy and Safety of Intravenous + Oral Vs. Oral Amiodarone in Preventing Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous amiodarone(2) CI brief — competitive landscape report
- Intravenous amiodarone(2) updates RSS · CI watch RSS
- Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud portfolio CI
Frequently asked questions about Intravenous amiodarone(2)
What is Intravenous amiodarone(2)?
How does Intravenous amiodarone(2) work?
What is Intravenous amiodarone(2) used for?
Who makes Intravenous amiodarone(2)?
Is Intravenous amiodarone(2) also known as anything else?
What drug class is Intravenous amiodarone(2) in?
What development phase is Intravenous amiodarone(2) in?
What are the side effects of Intravenous amiodarone(2)?
What does Intravenous amiodarone(2) target?
Related
- Drug class: All Class III antiarrhythmic agent drugs
- Target: All drugs targeting Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels
- Manufacturer: Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation with rapid ventricular response
- Indication: Drugs for Ventricular tachycardia
- Indication: Drugs for Ventricular fibrillation
- Also known as: 72 hour amiodarone
- Compare: Intravenous amiodarone(2) vs similar drugs
- Pricing: Intravenous amiodarone(2) cost, discount & access